地诺单抗哪有售？

What kind of medicine is it? Where can I buy it? Giant cell tumor of bone is a histologically benign but often aggressive skeletal tumor that mostly occurs in young adults aged 20 to 40 years old. The incidence rate in women is slightly higher than that in men, accounting for about 56.4%. Globally, giant cell tumor of bone accounts for approximately 4%-5% of all primary bone tumors. Compared with European and American populations, it is more common in China, accounting for approximately 20% of all primary bone tumors. Although the vast majority of giant cell tumors of bone are benign tumors, if left untreated, they often cause complete destruction of the affected bone, leading to fractures, joint dysfunction, or amputation. Giant cell tumor of bone is composed of stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK receptors. Its pathogenesis is that overexpression of RANKL causes tumor growth and bone destruction. RANKL is a transmembrane or soluble protein necessary for the formation, function, and survival of osteoclasts; osteoclasts are responsible for bone resorption, thereby regulating bone calcium release. Desosumab is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth. Desosumab inhibits tumor growth and reduces bone destruction by binding to RANKL and preventing it from activating RANK on the surface of osteoclasts, osteoclast precursors and osteoclast-like giant cells.

On May 27, 2019, Amgen China announced that: Denosumab Injection has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and weight ≥45 kg). In 2018, denosumab was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

Where can I buy denosumab? Although this drug is already on the market in my country, due to various reasons, it is not accessible to ordinary patients. Patients can only purchase it in countries and regions where denosumab is already on the market. It is worth mentioning that the price of denosumab, the original drug of Amgen in the United States, is the lowest in the world in Turkey. The specification of denosumab in Turkey is 125mg/1ml tube/box, and the price is equivalent to about $3,000 in RMB.

There are two ways for domestic patients to buy denosumab in Turkey: 1. If the patient is worried about buying counterfeit drugs, it is best to go directly to Turkey to buy denosumab. This can ensure the authenticity of the drug, so the patient can go to a Turkish hospital to buy the genuine product, and it is best to go to the top three hospitals in Turkey. 2. Domestic professional overseas medical service institutions can assist domestic patients to purchase genuine and guaranteed Turkish denosumab without going abroad. If you have any medication needs, you can consult the medical companion travel service for details.